ÖZET
Daha önce belirli endikasyonlar için tanımlanmış olan ilaçların yeni endikasyonlarda kullanımları ilacın yeniden amaçlandırılması/yeniden konumlandırılması olarak tanımlanmaktadır. Yeni ilaç geliştirmek için gereken sağlıklı gönüllülerden başlayan tüm klinik araştırma adımları, bunlara bağlı ilaç keşfinin yavaş ve ilacın piyasaya ulaşma süresinin uzun olması ve dolayısıyla da yüksek maliyet nedeniyle, yeni ilaç keşfi yerine eski ilaçların yeniden konumlandırılması farmakoekonomik bir çözüm olarak ortaya çıkmaktadır. Özellikle zamanın hayati önem taşıdığı ve acil ilaç geliştirilmesi gereken pandemi gibi durumlarda ilaçların yeniden değerlendirilmesi daha da önem kazanmaktadır. Bu derlemede hem ilacın yeniden konumlandırılması için kullanılan teknikleri özetledik, hem de hedef hastalık ve ilaç temelli olmak üzere 3 ana stratejiye bağlı olarak Koronavirüs Hastalığı-19 (COVİD-19) tedavisinde yeniden konumlandırılan ilaçları değerlendirdik. Eski ilaçların farmakovijilans çalışmalarının sonuçları ve uzun vadedeki toksik etkiler dahil görülebilecek yan etkilerin bilinmesi nedeniyle sepsis ve çoklu organ yetmezliğine gidebilen COVİD-19 enfeksiyonunun tedavisinde kullanılacak ilaçların keşfinde ilaçların yeniden konumlandırılması yöntemi geleneksel ilaç keşfine kıyasla önemli bir üstünlük olarak ortaya çıkmaktadır
References
1
Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatr. 2020;63:119-24.
2
Nosengo N. Can you teach old drugs new tricks? Nature 2016;534:314-6.
3
Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. J Pharm Pharmacol. 2020;72:1145-51. doi: 10.1111/jphp.13273.
4
Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, et al. Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg 2011;8:61-9.
5
Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011;7:146-57.
6
Dakshanamurthy S, Issa NT, Assefnia S, Seshasayee A, Peters OJ, Madhavan S, et al. Predicting new indications for approved drugs using a proteochemometric method. J Med Chem 2012;55:6832-48.
7
Dudley JT, Deshpande T, Butte AJ. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 2011;12:303-11.
8
Hodos RA, Kidd BA, Shameer K, Readhead BP, Dudley JT. In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 2016;8:186-210.
9
Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. Computational methods in drug discovery. Pharmacol Rev 2014;66:334-95.
10
Kharkar PS, Warrier S, Gaud RS. Reverse docking: a powerful tool for drug repositioning and drug rescue. Future Med Chem 2014;6:333-42.
11
Lee A, Lee K, Kim D. Using reverse docking for target identification and its applications for drug discovery. Expert Opin Drug Discov 2016;11:707-15.
12
Yuan Y, Pei J, Lai L. Binding site detection and druggability prediction of protein targets for structure-based drug design. Curr Pharm Des 2013;19:2326-33.
13
Gao Z, Li H, Zhang H, Liu X, Kang L, Luo X, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008;9:104.
14
Hurle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: from data to therapeutics. Clin Pharmacol Ther 2013;93:335-41.
15
Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014;506:376-81.
16
Nabirotchkin S, Peluffo AE, Rinaudo P, Yu J, Hajj R, Cohen D. Next-generation drug repurposing using human genetics and network biology. Curr Opin Pharmacol 2020;51:78-92.
17
Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet 2015;47:856-60.
18
Andronis C, Sharma A, Virvilis V, Deftereos S, Persidis A. Literature mining, ontologies and information visualization for drug repurposing. Brief Bioinform 2011;12:357-68.
19
Parisi D, Adasme MF, Sveshnikova A, Bolz SN, Moreau Y, Schroeder M. Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs. Comput Struct Biotechnol J 2020;18:1043-55.
20
Wang K, Chen W, Zhou Y-S, Lian J-Q, Zhang Z, Du P, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv 2020:2020.03.14.988345.
21
Wu R, Wang L, Kuo HD, Shannar A, Peter R, Chou PJ, et al. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep 2020:1-15.
22
Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 2020;181:894-904 e9.
23
Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020;10:766-88.
24
Durdagi S, Aksoydan B, Dogan B, Sahin K, Shahraki A, Birgül-İyison N. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike Receptor-Binding Domain Bound with ACE2 COVID19 Target Proteins: A Virtual Drug Repurposing Study. ChemRvix 2020. doi:10.26434/chemrxiv.12032712.v2.
25
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181:271-80 e8.
26
Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol 2012;86:6537-45.
27
Elmezayen AD, Al-Obaidi A, Sahin AT, Yelekci K. Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. J Biomol Struct Dyn 2020:1-13.
28
Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Sharman JL, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY. Nucleic Acids Res 2020;48:D1006-D21.
29
Bagherzadeh K, Daneshvarnejad K, Abbasinazari M, Azizian H. In silico repositioning for dual inhibitor discovery of sars-cov-2 (covid-19) 3c-like protease and papain-like peptidase. Preprints 2020. doi: 10.20944/preprints202004.0084.v1.
30
Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM, Smith CM, et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol 2004;7813600-12.
31
Subissi L, Imbert I, Ferron F, Collet A, Coutard B, Decroly E, et al. SARS-CoV ORF1b-encoded nonstructural proteins 12-16: replicative enzymes as antiviral targets. Antiviral Res 2014;101:122-30.
32
Simsek Yavuz S, Unal S. Antiviral treatment of COVID-19. Turk J Med Sci 2020;50:611-9.
33
Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222.
34
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
35
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19-preliminary report. N Eng J Med 2020;383:1813-26.
36
Nagata T, Lefor AK, Hasegawa M, Ishii M. Favipiravir: a new medication for the ebola virus disease pandemic. Disaster Med Public Health Prep2014;9:79-81.
37
Soliman EZ, Lundgren JD, Roediger MP, Duprez DA, Temesgen Z, Bickel M, et al. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS 2011;25:367-77.
38
Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. Current pharmacological treatments for COVID-19: What’s next? British Journal of Pharmacology. 2020. doi: 10.1111/bph.15072.
39
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Eng J Med 2020;382:1787-99.
40
Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395:1695-704.
41
Pécheur E-I, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, et al. The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses. J Virol 2016;90:3086.
42
Blaising J, Polyak SJ, Pecheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 2014;107:84-94.
43
Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 2020;12:eabb5883.
44
Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med 2020;217:e20200652.
45
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934-43.
46
Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv 2020:2020.03.11.987016.
47
Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020;117:10970.
48
Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England). 2020;395:e30-e1.
49
Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, Das SC, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A. 2011;108:12018-23.
50
Pattterson B, Seetthamraju H, Dhody K, Corley M, Kazempour K, Lalezari J, et al. Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19. Research Square 2020.doi: 10.1101/2020.05.02.20084673.
51
Barratt S, Medford AR, Millar AB. Vascular endothelial growth factor in acute lung injury and acute respiratory distress syndrome. Respiration 2014;87:329-42.
52
Wu R, Wang L, Kuo H-CD, Shannar A, Peter R, Chou PJ, et al. An Update on Current Therapeutic Drugs Treating COVID-19. Curr Pharmacol Rep 2020;6:56-70.
53
Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 2006;6:67-9.
54
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6:16.
55
Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020:105949.
56
Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020. doi:10.1016/S0140-6736(20)31180-6.
57
T.C. Sağlık Bakanlığı, Erişkin Hasta Yönetimi ve Tedavisi Rehberi. Last Accessed Date: 15.06.2020. Avaliable from: https://covid19bilgi.saglik.gov.tr/depo/tedavi/COVID19 EriskinHastaTedavisi.pdf.
58
Kamps BS, Hoffmann C. The new mini-textbook by Kamps & Hoffmann. 2nd ed. Germany: Steinhauser Verlag; 2020:115.
59
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Last Accessed Date:16.06.2020. Available from: https://www.covid19treatmentguidelines.nih.gov/.
60
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020;178:104787.
